[1]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081-1085.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(9):1081-1085.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
点击复制

21基因检测对早期Luminal A型乳腺癌治疗指导作用研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年9期
页码:
1081-1085
栏目:
临床研究
出版日期:
2021-09-05

文章信息/Info

Title:
Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer
作者:
韩金怡1; 2; 苏志勇1; 3
(1.锦州医科大学赤峰学院培养基地,内蒙古 赤峰 024000; 2.赤峰学院附属医院乳腺外科,内蒙古 赤峰 024000; 3.赤峰学院附属医院胸外科,内蒙古 赤峰 024000)
Author(s):
HAN Jinyi; SU Zhiyong
(Chifeng College Training Base of Jinzhou Medical University,Chifeng 024000,China)
关键词:
乳腺癌;  21基因检测;  Luminal A型;  复发风险;  预后因素
Keywords:
Breast cancer;  21-gene detection;  Luminal type A;  Recurrence risk;  Prognostic factor
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2021.09.010
文献标志码:
A
摘要:
目的:研究21基因检测对早期Luminal A型乳腺癌治疗指导作用。方法:选取早期Luminal A型乳腺癌患者174例,均接受手术治疗,完成21基因检测后得出复发风险分数(RS)。依据各项评估结果及RS分为低复发风险组及高复发风险组,结合美国国立综合癌症网络(NCCN)指南讨论后制定治疗方案,对低复发风险组进行单纯内分泌治疗(H方案),对高复发风险组进行化疗序贯内分泌治疗(CH方案)。分析21基因检测复发风险评估后决策变化,以及患者临床特征与RS的相关性。结果:21基因检测及RS评估前,初步确定66例适用于H方案,均为低复发风险者; 108例患者适用于CH方案,其中低风险者66例,中高风险者42例。经21基因检测并进行复发风险评估后决策发生变化,21基因检测及RS评估前后治疗方法比较存在统计学差异(P<0.01)。复发风险与年龄、绝经状态、肿瘤直径、病理组织学分级等无相关性(均P>0.05),而与Ki67表达及脉管癌栓相关(均P<0.01)。结论: 21基因检测对早期Luminal A型乳腺癌患者的治疗具有指导作用,可通过21基因检测给予RS替代既往年龄、肿瘤直径等作为独立预后因素。
Abstract:
Objective:To study the guiding role of 21-gene detection in the treatment of early Luminal type A breast cancer.Methods:174 patients with early Luminal type A breast cancer were enrolled.They all received surgical treatment and completed 21-gene detection,and the recurrence risk score(RS)was obtained.According to the evaluation results and RS,the patients were divided into low recurrence risk group and high recurrence risk group.A treatment plan was developed after discussing about the NCCN guidelines.The low recurrence risk group was treated with hormone therapy alone(H regimen),while the high recurrence risk group was treated with sequential treatment of chemotherapy and hormone therapy(CH regimen).Changes in decision-making after recurrence risk assessment via 21-gene detection,and the correlation between patient's clinical characteristics and RS were analyzed.Results:Before 21-gene detection and RS evaluation,preliminary analysis showed that 66 cases were suitable for H regimen,all of whom had low recurrence risk; 108 cases were suitable for CH regimen,including 66 low-risk cases and 42 medium and high-risk cases.After recurrence risk assessment via 21-gene detection,the determined treatment regimens changed.There were significant differences in treatment methods before and after 21-gene detection and RS assessment(P<0.01).There was no obvious correlation between recurrence risk and age,menopausal status,tumor diameter,and histopathological grade(all P>0.05),but it was related to the expression of Ki67 and vascular tumor thrombus(all P<0.05).Conclusion:The 21-gene detection plays a guiding role in the treatment of early Luminal type A breast cancer.The RS can be obtained through 21-gene detection,and then it can be used to replace independent prognostic factors such as age and tumor diameter.

参考文献/References:

[1] 韩丕华,宋张骏,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究[J].陕西医学杂志,2019,48(7):842-845.
[2] Sparano JA,Gray RJ,Makower DF,et al.Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J].N Engl J Med,2018,379(2):111-121.
[3] Sparano JA,Gray RJ,Makower DF,et al.Clinical outcomes in early breast cancer with a high 21-gene recurrencescore of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy:A secondary analysis of the tailorx randomized clinical trial[J].JAMA Oncol,2020,6(3):367-374.
[4] 魏 冰,任鹏飞,张成娟,等.分支DNA-液相芯片技术在乳腺癌21基因检测中的应用分析[J].医药论坛杂志,2017,38(11):11-14.
[5] 赵光楠,余海云,李文萍.Luminal A型乳腺癌术后复发转移的影响因素分析[J].中国实用医药,2020,15(11):16-18.
[6] Gradishar WJ,Anderson BO,Balassanian R,et al.NCCN guidelines insights breast cancer,version 1.2016[J].J Natl Compr Canc Netw,2015,13(12):1475-1485.
[7] Lee MH,Han W,Lee JE,et al.The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea[J].Cancer Res Treat,2015,47(2):208-214.
[8] Gradishar WJ,Anderson BO,Balassanian R,et al.Breast cancer,version 4.2017.NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2018,16(3):310-320.
[9] 韩丕华,袁 权.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值[J].陕西医学杂志,2020,49(7):889-892.
[10] 董华英,王 伟,陈元文,等.Luminal A型和HER-2阳性乳腺癌的肿瘤干细胞生物学行为比较[J].中国普通外科杂志,2017,26(11):1431-1438.
[11] 杨俊锋,郝艳方,王福科,等.防己黄芪汤对三阴性乳腺癌细胞MB-MDA-231抑制作用研究[J].陕西中医,2021,42(2):152-155,171.
[12] Woodward WA,Barlow WE,Jagsi R,et al.Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer[J].JAMA Oncol,2020,6(4):505-511.
[13] Poorvu PD,Gelber SI,Rosenberg SM,et al.Prognostic impact of the 21-gene recurrence score assay among young women with node-negative and node-positive ER-positive/HER2-negative breast cancer[J].J Clin Oncol,2020,38(7):725-733.
[14] 杨玉庆,黄美玲,李南林,等.21基因在乳腺癌患者复发风险评估中的临床意义[J].西部医学,2019,31(7):1030-1033,1042.
[15] 梁 跃,陈小松,吴佳毅,等.多学科模式下早期乳腺癌化疗决策改变的影响因素分析[J].中华肿瘤防治杂志,2015,22(22):1769-1773.
[16] Wang W,Lin L,Fei X,et al.21-gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes[J].Oncol Lett,2019,18(4):4346-4356.
[17] 洪 进,陈小松,毛 艳,等.Luminal A型早期乳腺癌化疗决策的影响因素分析[J].外科理论与实践,2014,19(5):407-411.
[18] Wu J,Fang Y,Lin L,et al.Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive,HER2-negative early breast cancer patients[J].Oncotarget,2017,8(24):38706-38716.
[19] 瞿飞麟,陈小松,宗 瑜,等.乳腺癌病人的21基因复发风险评分与临床病理特征[J].外科理论与实践,2017,22(3):240-247.
[20] 刘佳兴,谷家梦,左怀全.Luminal A型乳腺癌患者术后预后影响因素分析[J].中华肿瘤防治杂志,2019,26(1):38-42.
[21] 吴佳毅,靳 疆,陈伟国,等.乳腺黏液癌21基因复发风险评分与临床病理关系[J].外科理论与实践,2017,22(5):397-400.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(9):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(9):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(9):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(9):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[8]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(9):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[9]李福平,王 茂,邱春丽,等.莱菔硫烷联合维生素D对乳腺癌细胞增殖及凋亡的影响[J].陕西医学杂志,2022,51(8):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
　LI Fuping,WANG Mao,QIU Chunli,et al.Effect of sulforaphane combined with vitamin D on proliferation and apoptosis of breast cancer cells[J].,2022,51(9):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
[10]杜 森,赵 森,周 青,等.血清长链非编码RNA小核仁RNA宿主基因3检测联合核磁共振弥散加权成像在乳腺癌诊断中的应用[J].陕西医学杂志,2022,51(8):1021.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.027]
　DU Sen,ZHAO Sen,ZHOU Qing,et al.Value of serum lncRNA SNHG3 detectioncombined with MRI diffusion-weighted imaging in diagnosis of breast cancer[J].,2022,51(9):1021.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.027]

备注/Memo

备注/Memo:
基金项目:吴阶平医学基金会临床科研专项基金资助项目(320.6750.19089-106)
更新日期/Last Update: 2021-09-06